KLK2-targeted immunotherapies present a promising opportunity in prostate cancer treatment. Elevated KLK2 in tumors and its surface expression make it an accessible target. Success in preclinical ...

Trading with an implied upside of 60.5% and an RSI of 34.6, Tempus AI, Inc. (NASDAQ:TEM) has emerged as a notable oversold ...

Study reveals geographic differences in the use of innovative technological approaches to diagnose and treat prostate cancer. The study looked at the effect of regional hospital competition and ...

CHF 26.4 million (EUR 28.4 million) extension, led by existing investors, accelerates clinical development of NU101 and NU201 radiotheranostic ...

One in eight men will develop prostate cancer in their lifetime. Surgery to treat the disease can lead to unwelcome side effects. A minimally invasive alternative that avoids surgery is now available ...

Read more in the PNW Health series. Prostate cancer is the second-most common cancer among men in the U.S., affecting 13 out of every 100 American men over the course of their lifetime. About two to ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...